top of page
Lauren Sheu.JPG

Lauren Sheu

MD Candidate

Lauren is a medical student at the Pritzker School of Medicine (entering c/o of 2022). She graduated from Duke University in 2022 with a BS in Cell & Molecular Biology. Prior to medical school, Lauren worked at the labs of Drs. Edgar Engleman (Stanford) and Smita Nair (Duke), where she contributed to developing multiple cancer immunotherapies. She intends to specialize in Hematology/Oncology and hopes to become a physician scientist, using her clinical insights to inform continued research in cancer immunology. 

Current Research:

Lauren is working on adapting the lab's in vitro tumor-lymph node immune circuit as a clinical tool for predicting cancer immunotherapy responsivity. 


Linde IL, Prestwood TR, Qiu J, Pilarowski G, Linde MH, Zhang X, Shen L, Reticker-Flynn NE, Chiu DK, Sheu LY, Van Deursen S, Tolentino LL, Song WC, Engleman EG. Neutrophil-activating therapy for the treatment of cancer. Cancer Cell. 2023 Feb 13;41(2):356-372.e10. doi: 10.1016/j.ccell.2023.01.002. Epub 2023 Jan 26. PMID: 36706760; PMCID: PMC9968410.


Nief CA, Swartz AM, Chelales E, Sheu LY, Crouch BT, Ramanujam N, Nair SK. Ethanol Ablation Therapy Drives Immune-Mediated Antitumor Effects in Murine Breast Cancer Models. Cancers (Basel). 2022 Sep 25;14(19):4669. doi: 10.3390/cancers14194669. PMID: 36230591; PMCID: PMC9564135.


Ackerman SE, Pearson CI, Gregorio JD, Gonzalez JC, Kenkel JA, Hartmann FJ, Luo A, Ho PY, LeBlanc H, Blum LK, Kimmey SC, Luo A, Nguyen ML, Paik JC, Sheu LY, Ackerman B, Lee A, Li H, Melrose J, Laura RP, Ramani VC, Henning KA, Jackson DY, Safina BS, Yonehiro G, Devens BH, Carmi Y, Chapin SJ, Bendall SC, Kowanetz M, Dornan D, Engleman EG, Alonso MN. Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity. Nat Cancer. 2021 Jan;2(1):18-33. doi: 10.1038/s43018-020-00136-x. Epub 2020 Dec 7. PMID: 35121890; PMCID: PMC9012298.

bottom of page